GRI vs. HSTO, SBFM, ATNF, NLSP, NBSE, PBLA, CMRA, INM, PRFX, and GLMD
Should you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Histogen (HSTO), Sunshine Biopharma (SBFM), 180 Life Sciences (ATNF), NLS Pharmaceutics (NLSP), NeuBase Therapeutics (NBSE), Panbela Therapeutics (PBLA), Comera Life Sciences (CMRA), InMed Pharmaceuticals (INM), PainReform (PRFX), and Galmed Pharmaceuticals (GLMD). These companies are all part of the "pharmaceutical preparations" industry.
Histogen (NASDAQ:HSTO) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership.
GRI Bio has a net margin of 0.00% compared to GRI Bio's net margin of -65,142.11%. GRI Bio's return on equity of -136.13% beat Histogen's return on equity.
Histogen received 7 more outperform votes than GRI Bio when rated by MarketBeat users.
34.0% of GRI Bio shares are owned by institutional investors. 3.3% of Histogen shares are owned by insiders. Comparatively, 16.8% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, GRI Bio had 1 more articles in the media than Histogen. MarketBeat recorded 3 mentions for GRI Bio and 2 mentions for Histogen. Histogen's average media sentiment score of 0.33 beat GRI Bio's score of 0.30 indicating that GRI Bio is being referred to more favorably in the news media.
Histogen has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.77, suggesting that its stock price is 277% less volatile than the S&P 500.
Histogen has higher revenue and earnings than GRI Bio. Histogen is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Histogen beats GRI Bio on 7 of the 13 factors compared between the two stocks.
Get GRI Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
